Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis

Table 1 Preoperative clinical characteristics of SGC and MGC in the entire cohort (n = 4107) and after propensity score matching (n = 665)

Parameters	Entire cohort (before matching)		P value	Propensity score matched cohort		P value
Parameters	SGC, n (%)	MGC, n (%)	P value	SGC, n (%)	MGC, n (%)	P value
Age (years)			0.141			0.968
≤ 60	1871 (47.1)	54 (40.6)		215 (40.4)	54 (40.6)
> 60	2103 (52.9)	79 (59.4)		317 (59.6)	79 (59.4)
Sex			0.166			0.886
Male	2924 (73.6)	105 (78.9)		423 (79.5)	105 (78.9)
Female	1050 (26.4)	28 (21.1)		109 (20.5)	28 (21.1)
BMI (kg/m²)			0.467			0.947
BMI < 18.5	385 (9.7)	13 (9.8)		57 (10.7)	13 (9.8)
18.5 ≤ BMI < 25	2921 (73.5)	103 (77.4)		406 (76.3)	103 (77.4)
BMI ≥ 25	668 (16.8)	17 (12.8)		69 (13.0)	17 (12.8)
Family history^a			0.273			0.269
Absent	3736 (94.0)	126 (94.7)		518 (97.3)	126 (94.7)
Gastric cancer	128 (3.2)	6 (4.5)		11 (2.1)	6 (4.5)
Other malignancy	110 (2.8)	1 (0.8)		3 (0.6)	1 (0.8)
Tobacco use			0.754			0.965
No	2849 (71.7)	97 (72.9)		389 (73.1)	97 (72.9)
Yes	1125 (28.3)	36 (27.1)		143 (26.9)	36 (27.1)
Alcohol use			0.410			0.532
No	3657 (92.0)	125 (94.0)		507 (95.3)	125 (94.0)
Yes	317 (8.0)	8 (6.0)		25 (4.7)	8 (6.0)
ASA score			0.168			0.641
I	1954 (49.2)	57 (42.9)		241 (45.3)	57 (42.8)
II	1818 (45.7)	71 (53.4)		269 (50.6)	71 (53.4)
III	193 (4.9)	4 (3.0)		21 (3.9)	4 (3.0)
IV	9 (0.2)	1 (0.8)		1 (0.2)	1 (0.8)
Comorbidities^b			0.464			0.715
Absent	1226 (30.9)	88 (66.2)		343 (64.5)	88 (66.2)
Present	2748 (69.1)	45 (33.8)		189 (35.5)	45 (33.8)
cT stage			0.920			0.785
T1–T3	2074 (52.2)	70 (52.6)		287 (53.9)	70 (52.6)
T4	1900 (47.8)	63 (47.4)		245 (46.1)	63 (47.4)
cN stage			0.050			0.806
N0	1653 (41.6)	44 (33.1)		182 (34.2)	44 (33.1)
N+	2321 (58.4)	89 (66.9)		350 (65.8)	89 (66.9)

SGC solitary gastric cancers, MGC multiple gastric cancers, BMI body mass index, ASA American Society of Anesthesiologists, cT stage clinical tumor stage, cN stage clinical node stage, cN0 clinical node-negative, cN+ clinical node-positive
^aFamily history presence of cancer within the patients’ first- and second- degree relatives
^bComorbidities including hypertension, diabetic mellitus, heart disease (coronary atherosclerotic heart disease, arrhythmia, etc.), pulmonary disease (chronic obstructive pulmonary disease, asthma, pneumonia, etc.), central nervous system disease (cerebrovascular disease, neurodegenerative disease, etc.), liver disease (cirrhosis, hepatitis, etc.), renal disease (chronic kidney disease, nephritis, etc.), anemia, hypoalbuminemia, and hyperthyroidism

ISSN: 2523-3548